Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709096 · ClinicalTrials.gov registry record · Phase 2
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
A Phase 2 study, sponsored by BioPharmX.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02709096: Completed Phase 2 study, sponsored by BioPharmX.
NCT02709096 is a Phase 2 study that has completed, run by BioPharmX. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02709096, a Phase 2 study, has completed, sponsored by BioPharmX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.
Primary Outcome
P. Acnes cultures will be collected using the modified Kligman Method at each study visit. After plating, the samples will be cultured for 7 days and then evaluated.
Interventions
- DRUG BPX-01, 1% Topical Gel
- DRUG BPX-01 Vehicle Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
What the finished NCT02709096 record still lists
NCT02709096 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which BPX-01, 1% Topical Gel is the first listed.
NCT02709096 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02709096 about?
NCT02709096 is a clinical study titled "BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes". This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.
What is the current status of trial NCT02709096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-04. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02709096?
The interventions under investigation include: BPX-01, 1% Topical Gel (DRUG), BPX-01 Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT02709096?
This trial is sponsored by BioPharmX, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02709096's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia